SuperworthCorMedix EV/EBIT CRMD
Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2025.
- Today, Oct 23, 2026
- 2.3×
- Peer median
- 7.6×
CorMedix's EV/EBIT is 2.3× as of Oct 23, 2026.
The median for 10 large drugmakers of a similar size is 7.6×.
EV/EBIT over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 2.3× | 2.1× | 10.1× |
| 2025 | 10.4× | 8.2× | 62.9× |
Against its peers
Companies in Drug Manufacturers - General nearest CorMedix's size, closest first, today.
| Company | EV/EBIT |
|---|---|
| CRMDCorMedix | 2.3× |
| ZVRAZevra Therapeutics | 2.9× |
| IRWDIronwood Pharmaceuticals | 3.5× |
| PBYIPuma Biotechnology | 15.6× |
| COLLCollegium Pharmaceutical | 9.4× |
| ARVNArvinas | n/m |
| ABUSArbutus Biopharma | 4.9× |
| AMPHAmphastar Pharmaceuticals | 12.2× |
| OMEROmeros | n/m |
| PCRXPacira BioSciences | 7.6× |
| ANABAnaptysbio | n/m |
| Peer median | 7.6× |
Where CorMedix ranks
What the EV/EBIT tells you
What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.
Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.
More on CorMedix
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.